资金继续逆势加仓！恒生创新药ETF(520500)份额、规模齐创新高！

Group 1 - The core viewpoint of the article highlights the increasing interest and investment in the Hong Kong innovative pharmaceutical sector, despite recent market volatility [1][2] - The Hang Seng Innovative Pharmaceutical ETF (520500) has seen a net inflow of 109 million yuan on August 27, reaching new highs in both shares (710 million) and scale (1.392 billion yuan) since its inception [1] - The ETF has demonstrated strong trading activity with an average trading volume of 1.122 billion yuan in August, indicating high liquidity and investor interest in the innovative pharmaceutical sector [1] Group 2 - As the interim report disclosures near completion, market focus is shifting towards companies with significant R&D progress, procurement clearing, and overseas potential [1] - The innovative pharmaceutical sector in China is entering a phase of result realization, with many R&D catalysts expected to drive investment interest through 2025 [1] - Recent reports suggest that the liquidity narrative in the Hong Kong market is improving, which may support a rebound in stock prices and narrow the gap with the rapidly rising A-share market [1] Group 3 - The Hang Seng Innovative Pharmaceutical ETF (520500) tracks the Hang Seng Innovative Pharmaceutical Index, which includes high-growth companies in the pharmaceutical and biotechnology sectors, providing targeted exposure to core industry drivers [1] - The ETF's underlying index has a 100% "Hong Kong content" ratio, indicating a unique positioning and scarcity value in the market [1] - The fund manager, Huatai-PB Fund, has over 18 years of experience in ETF operations, managing over 550 billion yuan in ETF assets, placing it among the top tier in the industry [1]